Crimean-Congo hemorrhagic fever: Pathogenesis, transmission and public health challenges.

Abstract

The dangerous Crimean-Congo hemorrhagic fever virus (CCHFV), an encapsulated negative-sense RNA virus of the family Nairoviridae, is transmitted from person to person via ticks. With a case fatality rate between 10% to 40%, the most common ways that the disease may spread to humans are via tick bites or coming into touch with infected animals' blood or tissues. Furthermore, the transfer of bodily fluids between individuals is another potential route of infection. There is a wide range of symptoms experienced by patients throughout each stage, from myalgia and fever to extreme bruising and excess bleeding. Tick management measures include minimising the spread of ticks from one species to another and from people to animals via the use of protective clothing, repellents, and proper animal handling. In order to prevent the spread of illness, healthcare workers must adhere to stringent protocols. Despite the lack of an authorised vaccine, the main components of treatment now consist of preventative measures and supportive care, which may include the antiviral medicine ribavirin. We still don't know very much about the virus's mechanisms, even though advances in molecular virology and animal models have improved our understanding of the pathogenesis of CCHFV. A critical need for vaccination that is both safe and effective, as well as for quick diagnosis and efficient treatments to lessen the disease's impact in areas where it is most prevalent. Important steps towards lowering Crimean-Congo hemorrhagic fever mortality and morbidity rates were to anticipatethe future availability of immunoglobulin products.